EuroBiotech: More Articles of Note


> Rottapharm Biotech shared phase 2 data on CR4056 in chronic pain associated with osteoarthritis. The trial missed its primary endpoint but generated results to encourage Rottapharm that the drug works in patients with a certain phenotype. Release 

> Themis Bioscience began a phase 1 trial of its Zika virus vaccine. Statement 

> Eisai struck a deal with Numab top develop multispecific antibody cancer immunotherapies. Numab will receive an upfront payment plus milestones. Release  


Digitize remote site monitoring with Box

Box will discuss how your life sciences organization can continue to propel therapies & devices through the value chain with faster and even more secure site monitoring and auditing.

> Novo Holdings and Arix Bioscience co-led a €20 million ($22 million) series A financing in STipe Therapeutics. The funding will support efforts to modulate the STING pathway. Statement 

> Genfit appointed Dean Hum as president of its U.S. operation. Hum is relocating to the U.S. Release  

> Transgene shared clinical data on TG4001 in combination with Merck KGaA and Pfizer’s anti-PD-L1 immunotherapy. Three of the six HPV-positive cancer patients who received the higher dose of therapeutic vaccine TG4001 experienced durable partial responses. Statement 

Suggested Articles

IBM and Pfizer developed an artificial intelligence model that could eventually predict if a person will develop Alzheimer’s using a language test.

After teaming up with other Big Pharmas to bolster antibiotics research, Pfizer is adding a new antibiotic prospect to its pipeline.

The oral direct-acting antiviral is set to enter a phase 3 trial in non-hospitalized patients early next year.